Registry study of Suhexiang Pill after recent stroke
Part of Brain & nervous system, Heart & circulation clinical trials.
This study tracks people who had an ischemic stroke (a type of stroke caused by blocked blood flow) within the last week and received Suhexiang Pill. It aims to see how outcomes and follow-up go in real-world use, which may help doctors understand who might benefit and how to monitor patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had an ischemic stroke within 7 days of when symptoms started
- You are at least 18 years old
- You received Suhexiang Pill as part of your treatment
- You (or your legal representative) can sign informed consent
- You are not allergic to Suhexiang Pill
- You are not pregnant and not breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a traditional Chinese herb formula called Qingre Huatan to see if it can stop stroke symptoms from getting worse in the first few days. It is for people who have had an ischemic stroke within the last 48 hours and are at high risk for early decline.
This trial tests if adding the herbal injection Shuxuening to standard clot-busting treatment improves recovery for people having an ischemic stroke. It is for adults within 6 hours of symptom onset who are already receiving a clot-dissolving medication.
This registry collects information about people recently diagnosed with an acute ischemic stroke or a transient ischemic attack (TIA) at a specific hospital. It helps doctors understand patterns of care and outcomes, which can improve future treatment planning.
This trial tests whether a Chinese herbal pill called naoxuekang can help people recover from a bleeding stroke caused by high blood pressure. It is for people who have had a small to moderate bleed within the last week and are in stable condition.
This Phase 2 study tests LT3001 to improve recovery after an acute ischemic stroke (a stroke caused by blocked blood flow). It is designed for people who can be treated within 24 hours of symptom onset and who meet specific safety and health requirements.
This trial tests whether MT200605 can help people who recently had an ischemic stroke (a type of stroke caused by a blocked blood vessel). The drug is given within 24 hours of symptoms starting, and you may join even if you received clot-busting treatment already.
Hear when a new Ischemic Stroke trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.